Changing Innovation in the Pharmaceutical Industry: Globalization and New Ways of Drug Development
Editat de Andre Jungmittag, Guido Reger, Thomas Reissen Limba Engleză Hardback – 21 iun 2000
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 637.28 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 18 dec 2010 | 637.28 lei 6-8 săpt. | |
Hardback (1) | 641.20 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 21 iun 2000 | 641.20 lei 6-8 săpt. |
Preț: 641.20 lei
Preț vechi: 754.36 lei
-15% Nou
Puncte Express: 962
Preț estimativ în valută:
122.72€ • 127.64$ • 102.84£
122.72€ • 127.64$ • 102.84£
Carte tipărită la comandă
Livrare economică 14-28 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783540673576
ISBN-10: 3540673571
Pagini: 236
Ilustrații: XV, 216 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.44 kg
Ediția:2000
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3540673571
Pagini: 236
Ilustrații: XV, 216 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.44 kg
Ediția:2000
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
Professional/practitionerCuprins
1 Introduction.- 2 The National System of Innovation in the United States and Germany.- 3 Dynamics of the Markets and Market Structure.- 4 Innovation Process and Techno-scientific Dynamics.- 5 Generation, Transfer and Exploitation of New Knowledge.- 6 Internationalization of Research and Development in Pharmaceuticals.- 7 Case Study on New Therapies for Selected Autoimmune Diseases.- 8 Summary and Conclusions.- References.- A Top Twenty Pharmaceutical Companies with Subsidiaries.- B R&D Agreements in the Autoimmune Diseases Area.- C From the Call for Tender for the NIH Program “Autoimmunity Centers of Excellence” Released in May 1998 (NIH 1998).
Caracteristici
In-depth analysis of international changes in industrial innovation in the pharmaceutical industry Contains: interviews with pharma companies, analysis of patent data, analysis of alliances of pharma companies, case study on new therapies